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International Journal of Women's DermatologyEditorialHidradenitis suppurativa and intimacyIn this issue, Alavi et al. (2018) address the important problem of
sexual health in patients with hidradenitis suppurativa (HS). In a
cross-sectional, case-control study, Alavi et al. compare the quality
of life as measured by the Dermatologic Quality of Life Index with
four validated questionnaires on sexual health in 50 patients with
HS and matched controls (Finlay and Khan, 1994). The research
found that HS-related disturbances of sexual health could predict
72% of the Dermatologic Quality of Life Index score reduction in
men and 46% in women.
It is not the ﬁrst time that HS has been identiﬁed as a cause of im-
paired sexual health andhealth-related quality of life butmedical science
mostlyworks not by offering absolute associations but rather through in-
cremental data that substantiate a suspected association. Therefore, it is
important to have data from different populations to even out temporal,
social, cultural, economic, and other factors thatmay otherwise inﬂuence
our interpretation of data. Previous studies have documented similar
problems in Dutch and German populations (Janse et al., 2017; Kurek
et al., 2012). The important questions are, which aspects of HS are re-
sponsible, and how do we best help our patients?
Several aspects of this complex inﬂammatory skin disease may be
involved including general and local physical comorbidities. The gen-
eral physical comorbidities of HS such as metabolic syndrome and
cardiovascular disease may play an independent role in the impaired
sexual health of HS in both male and female patients (Miner et al.,
2012; Schulster et al., 2017). Similarly, more localized mechanical
problems due to arthritis may inﬂuence the sex life of patients
(Schneider-Burrus et al., 2016). These factors require awareness
from the dermatologist and often a collaboration in a multidisciplin-
ary setting with internal medicine specialists and others.
HS is not without symptoms itself, and physical problems may be
directly linked to the diagnosis of HS. Pain and itching are prominent
skin symptoms among patients and with the locations of the lesions
on skin that is often involved in sexual intimacy, disease control be-
comes of the utmost importance (Ring et al., 2016a, 2016b; Zouboulis
et al., 2015). Patients often have undisclosed but extensive self-
management regimes of HS-associated pains that need to be asked
for speciﬁcally to be identiﬁed (Ring et al., 2016a, 2016b). During a
clinical examination, the sizes of the affected areas have been found
to associate with pain (Vangipuram et al., 2016).
Most patients with HS, however, report having a sexual partner,
which suggests that the impairment is not absolute and therefore,
the psychological comorbidities also play a role. Patients with HS not
only score lower on quality of life questionnaires but also have signiﬁ-
cant scores on depression and anxiety indices, all of which has rele-
vance to impaired sexual health (Kouris et al., 2016; Shavit et al., 2015).2352-6475/© 2018 The Author. Published by Elsevier Inc. on behalf ofWomen's Dermato
creativecommons.org/licenses/by-nc-nd/4.0/).The psychological comorbidities are clinically highly signiﬁcant. A
recent nationwide Danish registry study found that patients with HS
have a signiﬁcantly higher risk of completed suicide than the rest of
the population, which indicates that psychological comorbidities
may be even more signiﬁcant to the lives of patients with HS than
their physical comorbidities although even here patients show a
higher overall mortality (Egeberg et al., 2016; Thorlacius et al.,
2018). For optimal management, this requires dermatologists to be
aware of these comorbidities and occasionally the collaboration
with clinical psychologists or psychiatrists.
Finally, and perhaps most importantly, the nature of the disease
may profoundly inﬂuence sexual health. The disease is stigmatizing
not due to the nature of the inﬂammatory lesions but the lay percep-
tion of the lesions as unclean (Esmann and Jemec, 2011; Matusiak
et al., 2010). This stigma is likely associated with low resilience, part-
ner violence, and a plethora of other negative elements in the lives of
patients with HS (Kirby et al., 2017; Sisic et al., 2017).
For this issue to be addressedmeaningfully, we need professional
empathy. All patients require our empathy but few dermatological
patients suffer from diseases with a similar negative effect on the
life-course of the average patient (Ibler and Jemec, 2013). In this con-
text, the paper by Alavi et al. is an important contribution to the liter-
ature and reminds us of the private plight of our patients. The paper
reminds us of the need to ask, to learn, and to empathize in order to
heal.
Gregor B.E. Jemec, MD, DMSc
Professor and Chair, Department of Dermatology
Zealand University Hospital, Roskilde; Health Sciences Faculty
University of Copenhagen, Denmark
E-mail address: gbj@regionsjaelland.dk
https://doi.org/10.1016/j.ijwd.2018.03.001References
Alavi A, Farzanfar D, Rogalska T, LowesMA. Quality of life and sexual health in patients
with hidradenitis suppurativa. Int J Womens Derm 2018;4:73–8.
Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and
all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol
2016;152:429–34.
Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: A qualitative
study. Acta Derm Venereol 2011;91:328–32.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure
for routine clinical use. Clin Exp Dermatol 1994;19:210–6.logic Society. This is an open access article under the CC BY-NC-ND license (http://
73Editorial / International Journal of Women's Dermatology 4 (2018) 70-73Ibler KS, Jemec GB. Cumulative life course impairment in other chronic or recurrent
dermatologic diseases. Curr Probl Dermatol 2013;44:130–6.
Janse IC, Deckers IE, van der Maten AD, Evers AW, Boer J, van der Zee HH, et al. Sexual
health and quality of life are impaired in hidradenitis suppurativa: A multicentre
cross-sectional study. Br J Dermatol 2017;176:1042–7.
Kirby JS, Butt M, Esmann S, Jemec GB. Association of resilience with depression and
health-related quality of life for patients with hidradenitis suppurativa. JAMA
Dermatol 2017;153:1263–9.
Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et al.
Quality of life and psychosocial implications in patients with hidradenitis
suppurativa. Dermatology 2016;232:687–91.
Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S. Pro-
found disturbances of sexual health in patients with acne inversa. J Am Acad
Dermatol 2012;67:422–8.
Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis
suppurativa. Acta Derm Venereol 2010;90:264–8.
Miner M, Esposito K, Guay A, Montorsi P, Goldstein I. Cardiometabolic risk and female
sexual health: The Princeton III summary. J Sex Med 2012;9:641–51.
Ring HC, Sørensen H, Miller IM, List EK, Saunte DM, Jemec GB. Pain in hidradenitis
suppurativa: A pilot study. Acta Derm Venereol 2016;96:554–6.RingHC, Theut Riis P, Miller IM, Saunte DM, Jemec GB. Self-reported painmanagement
in hidradenitis suppurativa. Br J Dermatol 2016;174:909–11.
Schneider-Burrus S, Witte-Haendel E, Christou D, Rigoni B, Sabat R, Diederichs G. High
prevalence of back pain and axial spondyloarthropathy in patients with
hidradenitis suppurativa. Dermatology 2016;232:606–12.
Schulster ML, Liang SE, Najari BB. Metabolic syndrome and sexual dysfunction. Curr
Opin Urol 2017;27:435–40.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in
3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015;
29:371–6.
Sisic M, Tan J, Lafreniere KD. Hidradenitis suppurativa, intimate partner violence, and
sexual assault. J Cutan Med Surg 2017;21:383–7.
Thorlacius L, Cohen AD, Gislason GH, Jemec GB, Egeberg A. Increased suicide risk in pa-
tients with hidradenitis suppurativa. J Invest Dermatol 2018;138:52–7.
Vangipuram R, Vaidya T, Jandarov R, Alikhan A. Factors contributing to depression and
chronic pain in patients with hidradenitis suppurativa: Results from a single-
center retrospective review. Dermatology 2016;232:692–5.
Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis
suppurativa/acne inversa: Criteria for diagnosis, severity assessment, classiﬁcation
and disease evaluation. Dermatology 2015;231:184–90.
